{
  "id": "06c066c5921b929b",
  "title": "C4 Therapeutics , Inc .: C4 Therapeutics Outlines Strategic Milestones to Advance Cemsidomide as a Potential Best - in - Class IKZF1 / 3 Degrader and Discovery Strategy Focused on Novel Targets in Clinically Validated Pathways",
  "description": "20260114T123000Z",
  "content": "",
  "source": "finanznachrichten.de",
  "source_url": "https://www.finanznachrichten.de/nachrichten-2026-01/67432329-c4-therapeutics-inc-c4-therapeutics-outlines-strategic-milestones-to-advance-cemsidomide-as-a-potential-best-in-class-ikzf1-3-degrader-and-discover-399.htm",
  "published_at": "20260114T123000Z",
  "fetched_at": "2026-01-15T00:21:56.842948+00:00",
  "category": "health_biotech",
  "subcategory": null,
  "keywords": [],
  "location": "Germany",
  "raw_data": {
    "url": "https://www.finanznachrichten.de/nachrichten-2026-01/67432329-c4-therapeutics-inc-c4-therapeutics-outlines-strategic-milestones-to-advance-cemsidomide-as-a-potential-best-in-class-ikzf1-3-degrader-and-discover-399.htm",
    "url_mobile": "",
    "title": "C4 Therapeutics , Inc .: C4 Therapeutics Outlines Strategic Milestones to Advance Cemsidomide as a Potential Best - in - Class IKZF1 / 3 Degrader and Discovery Strategy Focused on Novel Targets in Clinically Validated Pathways",
    "seendate": "20260114T123000Z",
    "socialimage": "https://www.finanznachrichten.de/chart-c4-therapeutics-inc-aktie-intraklein-nasdaq.png",
    "domain": "finanznachrichten.de",
    "language": "English",
    "sourcecountry": "Germany"
  }
}